$0.3571
At close: Apr 29 EDT
$0.3137
-0.04-12.15%
Pre-Market: 5:23 AM EDT
Comments
Loading...
Relmada Therapeutics Analyst Ratings and Price Targets | NASDAQ:RLMD | Benzinga
Relmada Therapeutics Inc has a consensus price target of $8.83 based on the ratings of 8 analysts. The high is $26 issued by Mizuho on June 15, 2023. The low is $1 issued by Mizuho on December 5, 2024. The 3 most-recent analyst ratings were released by Mizuho, Leerink Partners, and Jefferies on December 5, 2024, December 4, 2024, and September 17, 2024, respectively. With an average price target of $5 between Mizuho, Leerink Partners, and Jefferies, there's an implied 1493.88% upside for Relmada Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
Leerink Partners
Jefferies
Goldman Sachs
Mizuho
1calculated from analyst ratings
Analyst Ratings for Relmada Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 12/05/2024 | Buy Now | 218.78% | Mizuho | Uy Ear62% | $23 → $1 | Downgrade | Outperform → Neutral | Get Alert |
| 12/04/2024 | Buy Now | 218.78% | Leerink Partners | Marc Goodman73% | $10 → $1 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/17/2024 | Buy Now | 4044.09% | Jefferies | Andrew Tsai26% | $3.5 → $13 | Upgrade | Hold → Buy | Get Alert |
| 06/05/2024 | Buy Now | 537.55% | Goldman Sachs | Andrea Tan40% | $3 → $2 | Downgrade | Neutral → Sell | Get Alert |
| 06/15/2023 | Buy Now | 8188.17% | Mizuho | Vamil Divan75% | → $26 | Reiterates | Buy → Buy | Get Alert |
| 01/23/2023 | Buy Now | 3087.76% | SVB Leerink | Marc Goodman73% | $42 → $10 | Maintains | Outperform | Get Alert |
| 10/14/2022 | Buy Now | 2450.21% | Goldman Sachs | Andrea Tan40% | → $8 | Downgrade | Buy → Neutral | Get Alert |
| 10/14/2022 | Buy Now | — | Guggenheim | Yatin Suneja49% | — | Downgrade | Buy → Neutral | Get Alert |
| 10/13/2022 | Buy Now | — | Oppenheimer | Jay Olson61% | — | Downgrade | Outperform → Perform | Get Alert |
| 09/23/2022 | Buy Now | 25720.85% | Goldman Sachs | Andrea Tan40% | $49 → $81 | Maintains | Buy | Get Alert |
| 09/06/2022 | Buy Now | 19026.55% | Guggenheim | Yatin Suneja49% | $50 → $60 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 20301.66% | Oppenheimer | Jay Olson61% | $75 → $64 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Relmada Therapeutics (RLMD) stock?
The latest price target for Relmada Therapeutics (NASDAQ:RLMD) was reported by Mizuho on December 5, 2024. The analyst firm set a price target for $1.00 expecting RLMD to rise to within 12 months (a possible 218.78% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Relmada Therapeutics (RLMD)?
The latest analyst rating for Relmada Therapeutics (NASDAQ:RLMD) was provided by Mizuho, and Relmada Therapeutics downgraded their neutral rating.
When was the last upgrade for Relmada Therapeutics (RLMD)?
The last upgrade for Relmada Therapeutics Inc happened on September 17, 2024 when Jefferies raised their price target to $13. Jefferies previously had a hold for Relmada Therapeutics Inc.
When was the last downgrade for Relmada Therapeutics (RLMD)?
The last downgrade for Relmada Therapeutics Inc happened on December 5, 2024 when Mizuho changed their price target from $23 to $1 for Relmada Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Relmada Therapeutics (RLMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relmada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relmada Therapeutics was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.
Is the Analyst Rating Relmada Therapeutics (RLMD) correct?
While ratings are subjective and will change, the latest Relmada Therapeutics (RLMD) rating was a downgraded with a price target of $23.00 to $1.00. The current price Relmada Therapeutics (RLMD) is trading at is $0.31, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
